US Patent

US11458119 — Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Composition of Matter · Assigned to Genzyme Corp · Expires 2030-11-24 · 5y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects amorphous and crystalline forms of the compound genz 112638 hemitartrate, which can be used to inhibit glucosylceramide synthase.

USPTO Abstract

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

Drugs covered by this patent

Patent Metadata

Patent number
US11458119
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-11-24
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.